FX.co ★ Teva Presents IMPACT-TD Data On Tardive Dyskinesia, Revealing Patient Experience Variations

Teva Pharmaceuticals, a U.S. branch of Teva Pharmaceutical Industries Ltd. (TEVA), has released new interim findings from its Phase 4 IMPACT-TD Registry study, highlighting the differing impacts of tardive dyskinesia (TD) on patients with psychotic disorders versus those with mood disorders.

The IMPACT-TD Registry represents the most extensive study to date examining the comprehensive effects of TD, documenting real-world treatment patterns and results when using once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO tablets. Additionally, Teva has shared interim data from a patient survey detailing initial real-world experiences with AUSTEDO XR.

This dual-phase IMPACT-TD study is a thorough three-year observational effort to understand how TD progresses and affects patients' quality of life, particularly focusing on outcomes linked to the treatment with AUSTEDO XR and AUSTEDO.

Findings from IMPACT-TD indicate that individuals with psychotic disorders are less frequently diagnosed with TD compared to those with mood disorders, with diagnosis rates at 36% and 50%, respectively, despite both groups recording similar average AIMS (Abnormal Involuntary Movement Scale) scores (8.7 for psychotic disorders versus 8.0 for mood disorders). Patients with psychotic disorders exhibited a longer median duration since recognizing movement abnormalities (5.5 years compared to 3.8 years) and since first using an antipsychotic medication (16 years versus 10 years).

Within the study, the demographic composition revealed that patients with psychotic disorders (n=135) were typically younger, with an average age of 48, compared to 55.5 years for those with mood disorders (n=141). A larger proportion of psychotic disorder patients identified as Black or African American (36% compared to 9%) and were more frequently male (62% versus 38%).

Despite these demographic differences, the perceived impact of TD on patients' lives was reported as similar for both groups. Clinicians noted a moderate to severe impact on 86% of patients with psychotic disorders and 80% of those with mood disorders.

Teva also highlighted insights from a non-interventional, prospective, cross-sectional survey assessing real-world experiences of adults with TD or Huntington's disease chorea who were prescribed AUSTEDO XR. This survey evaluated patient-reported ease of use, effectiveness, and satisfaction with the medication.

In the interim data analysis from 131 respondents, 87% expressed satisfaction with AUSTEDO XR. Additionally, 74% observed improvements in their involuntary movements, and over 76% agreed that reducing these movements improved their social comfort and emotional well-being. More than half reported that this reduction positively influenced their overall physical health and balance between work, school, and life. Notably, 98% found the medication easy to integrate into their daily schedules, and 95% indicated they would continue using it.